Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

Projecting Survival for Patients Treated With First-Line Ipilimumab-Nivolumab Combination Therapy Using a Prognostic Model and Cost Per Responder Model of Ipilimumab-Nivolumab Combination Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03438279

Enrollment

600

Registered

2018-02-19

Start date

2015-06-23

Completion date

2017-12-28

Last updated

2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Brief summary

This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.

Interventions

OTHERNon-Interventional

Non-Interventional

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of melanoma

Exclusion criteria

* Age less than 18 years old

Design outcomes

Primary

Measure	Time frame	Description
Prognostic Model of Overall Survival (OS)	10 years	The OS prognostic model uses Individual patient data from a pooled analysis of 12 ipilimumab studies.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026